Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia

Honer, William G., Thornton, Allen E., Chen, Eric Y.H., Chan, Raymond C.K., Wong, Jessica O.Y., Bergmann, Andrea, Falkai, Peter, Pomarol-Clotet, Edith, McKenna, Peter J., Stip, Emmanuel, Williams, Richard, MacEwan, G. William, Wasan, Kishor, Procyshyn, Ric·2006·New England Journal of Medicine
DOI 10.1056/nejmoa053222

Cited by (275)

Items 101–200 of 275

  1. Cognitive–behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT
    Anthony P. Morrison, Melissa Pyle, Andrew Ian Gumley, Matthias Schwannauer, Douglas Turkington, Graeme MacLennan, John D. Norrie, Jemma Hudson, Samantha E. Bowe, Paul French et al. · 2019 · Health Technology Assessment
  2. Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms
    Jung Suk Lee, Je‐Yeon Yun, Shi Hyun Kang, Seung Jae Lee, Joonho Choi, Beomwoo Nam, Seung‐Hwan Lee, Young‐Chul Chung, Chan‐Hyung Kim · 2020 · Clinical Psychopharmacology and Neuroscience
  3. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002–2012)
    Qian Li, Yu‐Tao Xiang, Yun‐Ai Su, Liang Shu, Xin Yu, Christoph U. Correll, Gabor S. Ungvari, Helen F.K. Chiu, Cui Ma, Gaohua Wang et al. · 2015 · Schizophrenia Research
  4. A translational research approach to poor treatment response in patients with schizophrenia: clozapine–antipsychotic polypharmacy
    William G. Honer, Ric M. Procyshyn, Eric Yu Hai Chen, G. William MacEwan, Alasdair M. Barr · 2009 · Journal of Psychiatry and Neuroscience
  5. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series
    Se Hyun Kim, Dong Chung Jung, Yong Min Ahn, Yong Sik Kim · 2009 · Journal of Psychopharmacology
  6. A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia
    Hugo Geerts, P Roberts, Äthan Spiros · 2013 · CPT Pharmacometrics & Systems Pharmacology
  7. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?
    Valerie M. Anderson, Meghan McIlwain, Robert R. Kydd, Bruce R. Russell · 2015 · Psychiatry Research
  8. Positive impact of clinical pharmacist interventions on antipsychotic use in patients on excessive polypharmacy evidenced in a retrospective cohort study
    Matej Štuhec, Katja Gorenc · 2019 · GLOBAL PSYCHIATRY ARCHIVES
  9. Long-Term Efficacy and Tolerability of Clozapine Combined with Ziprasidone or Risperidone
    Anna Kuwilsky, B. Krumm, Susanne Englisch, Harald Raimund Dreßing, Mathias Zink · 2010 · Pharmacopsychiatry
  10. Schizophrenia Treatment Guidelinesin the United States
    Troy A. Moore · 2011 · Clinical Schizophrenia & Related Psychoses
  11. Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
    Irene Bighelli, Alessandro Rodolico, Spyridon Siafis, Myrto T. Samara, Wulf‐Peter Hansen, Salvatore Salomone, Eugenio Aguglia, Pierfelice Cutrufelli, Ingrid Oliveira Bosenbecker Bauer, Lio Bäckers et al. · 2022 · Cochrane Database of Systematic Reviews
  12. Effects of sertindole on cognition in clozapine‐treated schizophrenia patients
    René Ernst Nielsen, Sten E. Levander, Dorrit Thode, Jimmi Nielsen · 2012 · Acta Psychiatrica Scandinavica
  13. Antipsychotic Drugs and Dysregulated Glucose Homeostasis
    Emily C. C. Smith, Sri Mahavir Agarwal, Kristoffer J. Panganiban, Kateryna Maksyutynska, Jonathan Monteiro, Jiwon Lee, Femin Prasad, Andrew Ji, Divia Shah, Samantha Cavalier et al. · 2025 · JAMA Psychiatry
  14. Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment
    Andrea de Bartolomeis, Livia Avvisati, Felice Iasevoli, Carmine Tomasetti · 2013 · European Journal of Pharmacology
  15. Dandy-Walker Malformation-Like Condition Revealed by Refractory Schizophrenia: A Case Report and Literature Review
    Maxime Tréhout, Norbert Zhang, Marie Blouet, Alin Borha, Sonia Dollfus · 2018 · Neuropsychobiology
  16. Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders
    Philip S. Wang, ROBERT K. HEINSSEN, Molly Oliveri, Ann Wagner, Wayne K. Goodman · 2008 · Neuropsychopharmacology
  17. Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders
    Stéphane Potvin, Ginette Aubin, Émmanuel Stip · 2014 · European Archives of Psychiatry and Clinical Neuroscience
  18. Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial
    Melissa Pyle, John D. Norrie, Matthias Schwannauer, David Kingdon, Andrew Ian Gumley, Douglas Turkington, Rory Edward Byrne, Suzy Syrett, Graeme MacLennan, Robert E. J. Dudley et al. · 2016 · BMC Psychiatry
  19. Determination of Clozapine and its Metabolite, Norclozapine in Various Biological Matrices Using High-Performance Liquid Chromatography
    Micheal Rosland, Priscilla Szeto, Ric M. Procyshyn, Alasdair M. Barr, Kishor M. Wasan · 2007 · Drug Development and Industrial Pharmacy
  20. Augmentation strategies for clozapine resistance: a systematic review and meta-analysis
    Sandeep Grover, Siddharth Sarkar, Swapnajeet Sahoo · 2022 · Acta Neuropsychiatrica
  21. Combined Treatment With Amisulpride in Patients With Schizophrenia Discharged From a Short-Term Hospitalization Unit
    Juan de Dios Molina, Iván Lerma-Carrillo, M. Leonor, Fernando Pascual, Hilario Blasco-Fontecilla, Silvia González‐Parra, Francisco Javier Lopez-Munoz, Cecilio Álamo · 2008 · Clinical Neuropharmacology
  22. Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used?
    Robert J. Constantine, Ross Andel, Marie McPherson, Rajiv Tandon · 2017 · Psychiatry Research
  23. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports
    Alexander Hodkinson, Carl J. Heneghan, Kamal Ram Mahtani, Evangelos Kontopantelis, Maria Panagioti · 2021 · BMC Medicine
  24. Polypharmazie in der Behandlung der Schizophrenie
    Thomas Messer, Cordula Tiltscher, Max Schmauß · 2009 · Springer eBooks
  25. Drug Class Review: Atypical Antipsychotic Drugs
    Marian S. McDonagh, Kim Peterson, Susan Carson, Rochelle Fu, Sujata Thakurta · 2010
  26. Schizophrenia: synthetic strategies and recent advances in drug design
    Maria Azmanova, Anaïs Pitto‐Barry, Nicolas P. E. Barry · 2018 · MedChemComm
  27. Pharmacological treatments for schizophrenia
    Stephen R. Marder, Peter Brian Jones · 2008 · Cambridge University Press eBooks
  28. Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden
    John Teilmann Larsen, Maria V. Fagerquist, Mette Holdrup, Bjarne Christensen, Catarina Sigalin, Peter M. Nilsson · 2010 · Nordic Journal of Psychiatry
  29. Treatment-refractory schizophrenia: what is it and what has been done about it?
    Leslie Citrome · 2011 · Neuropsychiatry
  30. Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis
    Lik Hang N. Lee, Ric M. Procyshyn, Randall F. White, Todd Stephen Woodward, William G. Honer, Alasdair M. Barr · 2018 · PLoS ONE
  31. Pattern classification as decision support tool in antipsychotic treatment algorithms
    Alexandra I. Korda, Christina Andreou, Stefan Borgwardt · 2021 · Experimental Neurology
  32. Psychiatric Drug Use Among Patients of a Community Mental Health Service
    Natasa Gisev, J. Simon Bell, Andrew J. McLachlan, Manoranjenni Chetty, Timothy Frank Chen · 2006 · Disease Management & Health Outcomes
  33. Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients
    Lucia Sara Volonteri, Giancarlo Cerveri, Ilaria Francesca De Gaspari, Marialuisa Baldi, M. L. Rolandi, Pietro Papa, Massimo Carlo Mauri, Claudio Mencacci · 2010 · Psychopharmacology
  34. Clozapine: Current perspective
    RamKumar Solanki, Paramjeet Singh, MukeshK Swami · 2007 · Indian Journal of Psychiatry
  35. Antipsychotic polypharmacy: a needle in a haystack?
    Amaia López de Torre, Unax Lertxundi, Rafael Hernández, Juan Medrano · 2012 · General Hospital Psychiatry
  36. Development and Delivery of a Quality Improvement Program to Reduce Antipsychotic Polytherapy
    Jessica L. Gören, Stuart Beck, Barry J. Mills, Derri L. Shtasel, Robert L. Dufresne · 2010 · Journal of Managed Care Pharmacy
  37. Pharmakotherapie der Schizophrenie
    W. Wolfgang Fleischhacker, Martina Hummer · 2006 · Der Nervenarzt
  38. Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study
    Bogdan Patrichi, Cristiana Ţăpoi, Radu-Stefan Rogojina, Irina Bedreagă, Anca Dumitrache, Andreea Itu, Radu Dragomir, Adela Georgiana Buciuc · 2021 · Experimental and Therapeutic Medicine
  39. Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy
    Waleed M. Sweileh, Jihad Bani Odeh, Sa’ed H. Zyoud, Ansam F. Sawalha, Manal S Ihbeasheh · 2013 · BMC Psychiatry
  40. Psychoactive Prescription Practices for Serious Mental and Neurological Illness in Ghana: Data from the Mental Health and Poverty Project (MHaPP)
    Maureen Canavan, Heather L. Sipsma, Helen E. Jack, Sammy Ohene, Robert M. Rohrbaugh, Elizabeth H. Bradley, Angela L. Ofori-Atta, the MHaPP Research Consortium · 2016 · International Journal of Mental Health
  41. The Pitfalls of Psychotropic Polypharmacy
    Anthony J. Rothschild · 2021 · Journal of Clinical Psychopharmacology
  42. The Pharmacoepidemiology of Psychiatric Medications
    Philip S. Wang, Alan M. Brookhart, Christine M. Ulbricht, Sebastian Schneeweiß · 2011 · Wiley eBooks
  43. Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?
    Justin Faden, Natasha Kiryankova-Dalseth, Ruby Barghini, Leslie Citrome · 2020 · Expert Opinion on Pharmacotherapy
  44. Clozapine and Amisulpride in Refractory Schizophrenia and Alcohol Dependence
    Alain Dervaux, Joelle Cazali · 2007 · Journal of Clinical Psychopharmacology
  45. Augmentation of Aripiprazole with Low‐Dose Clozapine
    Steven C. Stoner, Megan M. Dahmen, Arnaldo Berges, Whitney M. Petry · 2007 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  46. Cognition and Plasma Ratio of Clozapine to N-desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia
    Allen E. Thornton, Ric M. Procyshyn, Alasdair M. Barr, G. William MacEwan, William G. Honer · 2015 · American Journal of Psychiatry
  47. Clozapine Alone versus Clozapine and Risperidone for Refractory Schizophrenia
    Guido Grass, Martin Hellmich, F Markus Leweke · 2006 · New England Journal of Medicine
  48. Quantitative Systems Pharmacology: Applications and Adoption in Drug Development
    Saroja Ramanujan, Kapil G. Gadkar, Ananth Kadambi · 2016 · AAPS advances in the pharmaceutical sciences series
  49. Explicit versus implicit review to explore combination antipsychotic prescribing
    Amanda Wheeler · 2009 · Journal of Evaluation in Clinical Practice
  50. Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients
    Yanzhe Li, Minghuan Zhu, Yeqing Dong, Nannan Liu, Xinxu Wang, Bing Yang, Zezhi Li, Shen Li · 2024 · European Archives of Psychiatry and Clinical Neuroscience
  51. Changes in Antipsychotic Medication in Clients of Assertive Community Treatment in Japan: A One-Year Follow Up
    Naoko Satake, Kyoko Hazama, Tamaki Sono, Makoto Takahashi, Junichiro Ito · 2011 · Clinical Practice and Epidemiology in Mental Health
  52. The Effect of Clozapine on Self-reported Duration of Sleep and Its Interaction With 23 Other Medications
    Emilio Fernández-Egea, Shanquan Chen, Christopher Jenkins, Concha Turrion, Simon Mitchell, David Dodwell, Louisa Mann, Julia Deakin, Zahoor H. Syed, Sepehr Hafizi et al. · 2021 · Journal of Clinical Psychopharmacology
  53. Underuse of recommended treatments among people living with treatment-resistant psychosis
    Julia Lappin, Kimberley Davies, Maryanne O׳Donnell, Ishan C. Walpola · 2022 · Frontiers in Psychiatry
  54. Augmenting Clozapine Response in Treatment-Resistant Schizophrenia
    Gary J. Remington · 2010 · Advances in biological psychiatry
  55. Schizophrenia and Related Psychoses
    2021 · Wiley eBooks
  56. Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled Trials
    Archana Mishra, Rituparna Maiti, Biswa Ranjan Mishra, Anand Srinivasan · 2023 · Clinical Psychopharmacology and Neuroscience
  57. Changes in drug prescription patterns in schizophrenia in five years
    Akfer Karaoğlan Kahiloğulları, Sibel Örsel, Ahmet Emre Sargın, Uğur Hatıloğlu, M.Sezai Berber, Musa Özbay · 2008 · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology
  58. Pharmacotherapy Update: Risperidone in the Treatment of Schizophrenia
    Michele Raja · 2009 · Clinical Medicine Therapeutics
  59. Adjunctive Treatment With Risperidone in Clozapine-Resistant Schizophrenia
    Iván Lerma-Carrillo, Juan de Dios Molina, T. Cuevas-Duran, Silvia González‐Parra, Hilario Blasco-Fontecilla, Cristina Andrade‐Rosa, Francisco Javier Lopez-Munoz, Cecilio Álamo · 2007 · Clinical Neuropharmacology
  60. Aripiprazole in Treatment-refractory Schizophrenia
    Wen‐Yu Hsu, Chien-I Lee, Nan‐Ying Chiu, David A Kahn · 2009 · Journal of Psychiatric Practice
  61. Prevalence of Antipsychotic Polypharmacy: Prescribing Practices at the Psychiatry Department at HMC (Hamad Medical Corporation, Doha, Qatar)
    Adel Zaraa · 2015 · Journal of Psychology & Clinical Psychiatry
  62. Clozapine antipsychotic polypharmacy: audit of use and patient monitoring
    Sam Wilson, Ross Hamilton, John S. Callender, Angela MacManus, Sheila Howitt, Blessing Okpo · 2013 · The Psychiatrist
  63. When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia
    Domenico De Berardis, Michele Fornaro, Annalisa Anastasia, Federica Vellante, Alessandro Valchera, Marilde Cavuto, Giampaolo Perna, Marco Di Nicola, Gianluca Serafini, Alessandro Carano et al. · 2018 · Springer eBooks
  64. Rationale for Emphasis on Management over Treatment of Schizophrenia in Clinical Practice
    Mohiuddin Ahmed, David N. Osser, Charles M. Boisvert, Lawrence G Albert, Masood Aslam · 2007 · Annals of Pharmacotherapy
  65. What's new in the other general journals
    Alison Tonks · 2006 · BMJ
  66. The 7 Sins of Psychopharmacology
    Carl Salzman, Ira D. Glick, Matcheri S. Keshavan · 2010 · Journal of Clinical Psychopharmacology
  67. Recent Trends of Antipsychotics Polypharmacy in Schizophrenia
    Jhin Goo Chang, Daeyoung Dave Roh, Chan Hyung Kim · 2013 · 대한정신약물학회지
  68. Polypharmazie bei schizophrenen Psychosen
    Mathias Zink, Susanne Englisch, Andreas Meyer‐Lindenberg · 2010 · Der Nervenarzt
  69. What Can We Do If Clozapine Fails? Pharmacologic Choices and Differential Outcomes
    David Jonathan Castle, Nicholas A Keks · 2014 · Springer eBooks
  70. Psychological Autopsy: Reconstructing the Mystery of Suicide
    Abdul Majid, Ajaz Ahmad Suhaff, Abdul Walid Khan · 2017 · Indian Journal of Private Psychiatry
  71. Role of electroconvulsive therapy in patients with clozapine-refractory schizophrenia
    Matej Markota, Paul E. Croarkin, Melanie Tara Gentry, Jonathan G. Leung · 2024 · Schizophrenia Research
  72. In vitroandin vivoevaluation of the inhibition potential of risperidone toward clozapine biotransformation
    Manoranjenni Chetty, Fabrizio D’Esposito, Wei V. Zhang, John Glen, Glenys Marie Dore, Zvijezdana Stankovic, Robert J. Edwards, Iqbal M. Ramzan, Michael T. Murray · 2009 · British Journal of Clinical Pharmacology
  73. Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
    Young Sup Woo, Joo Eon Park, Do‐Hoon Kim, InKi Sohn, Tae-Yeon Hwang, Young Min Park, Duk‐In Jon, Jong‐Hyun Jeong, Won‐Myong Bahk · 2016 · Psychiatry Investigation
  74. Treatment of Clozapine Nonresponders
    Sandeep Grover, Swapnajeet Sahoo · 2019 · Current Treatment Options in Psychiatry
  75. Positive impact of clinical pharmacist interventions on antipsychotic use in patients on excessive polypharmacy evidenced in a retrospective cohort study
    Matej Štuhec, M. Pharm, Katja Gorenc · 2020 · GLOBAL PSYCHIATRY ARCHIVES
  76. Adjunctive Versus Monotherapeutic Treatment for Schizophrenia: Addressing Antipsychotic Side Effects
    Monica Hazra, David C. Mamo, Gary J. Remington · 2008 · American Journal of Psychiatry
  77. Incidence of Antipsychotic-Associated Side Effects: Impact of Clinician Versus Patient Ratings and Change Versus Absolute Scores
    H. Takeuchi, G. Fervaha, G. Remington · 2016 · Journal of Clinical Psychopharmacology
  78. Clinical Psychopharmacology
    Matthew A. Fuller · 2016 · Springer eBooks
  79. Glucose Abnormalities in Schizophrenia, Bipolar and Major Depressive Disorders
    Chris Bushe · 2008 · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry
  80. Enquête observationnelle de prescription de la clozapine au centre hospitalier Charles-Perrens à Bordeaux, plus de 15 ans après l’AMM en France
    C. Mercier, P. Bret, M.-C. Bret, Emmanuelle Queuille · 2009 · L Encéphale
  81. Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza
    Guy M. Goodwin, Wolfgang Fleischhacker, Celso Arango, Pierre Baumann, Michael Davidson, Marc D. Binder, Peter Falkai, Shitij Kapur, Stefan Leucht, Rasmus Wentzer Licht et al. · 2011 · Psiquiatría Biológica
  82. Ziprasidone as Adjunctive Therapy in Severe Bipolar Patients Treated with Clozapine
    Natalia Bartolommei, Francesco Casamassima, Laura Pensabene, Federica Luchini, Antonella Benvenuti, Antonello Di Paolo, Luca Cosentino, Mauro Mauri, Lorenzo Lattanzi · 2014 · ISRN Psychiatry
  83. Addition of Aripiprazole to the Clozapine May Be Useful in Reducing Anxiety in Treatment-Resistant Schizophrenia
    Aleksandar Chanachev, Nicolas Ansermot, Séverine Crettol, Ute Nowotka, Maria-Eleni Stamatopoulou, Philippe Conus, Chin B. Eap · 2011 · Case Reports in Psychiatry
  84. Optimizing Clozapine Treatment
    Sachin Phansalkar, David N. Osser · 2009 · Psychopharm Review
  85. Psychopharmacological Approaches
    Leslie Citrome · 2013
  86. Evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: A simulation study of clinical data
    Archana Mishra, Rituparna Maiti, Mathan Kumar Ramasubbu, Anand Srinivasan · 2024 · Psychiatry Research
  87. Cognitive functions in schizophrenia: the interplay between blood viscosity, serum osmolarity, and symptom severity
    İpek Özönder Ünal, Miray Pirincci Aytac, Derya Adalı Aker, Tomris Duymaz, Tonguç Demir Berkol · 2025 · BMC Psychiatry
  88. Les associations d’antipsychotiques en psychiatrie : étude multicentrique sur les co-prescriptions de psychotropes associées à l’aripiprazole (étude ARIPSY-Est)
    Hervé Javelot, Thierry Javelot, M. El Aatmani, P. Noiriel, E. Tissot, Jacopo Tosi, Jean-Frédéric Westphal, Cathy Nonnenmacher, Michaël Messaoudi · 2011 · Le Pharmacien Hospitalier et Clinicien
  89. Combination and augmentation strategies in treatment-resistant schizophrenia
    Susanne Englisch, Mathias Zink · 2011 · Drug Discovery Today Therapeutic Strategies
  90. Refractory schizophrenia treated with clozapine combined with zuclopenthixol
    Wiesław Jerzy Cubała, Hubert Wichowicz, Jerzy Landowski · 2006 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  91. Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice
    Douglas Lee Boggs, Deanna L. Kelly, Raymond C. Love, Robert P. McMahon, Robert R. Conley · 2008 · Psychiatric Quarterly
  92. Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
    Julie A. Kreyenbuhl, Steven C. Marcus, Joyce C. West, Joshua E. Wilk, Mark Olfson · 2008 · FOCUS The Journal of Lifelong Learning in Psychiatry
  93. Şizofrenide Kombinasyon Tedavileri
    Vesile Altınyazar, Nevzat Yüksel · 2011 · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology
  94. A Retrospective Analysis of Antipsychotic Medication Use with Concomitant Clinical Evaluation in Outpatient Psychiatry Department in Palestine
    Manal S Ihbeasheh, Ikhlas S. Jarar, Waleed M. Sweileh · 2014 · Advances in Pharmacology and Pharmacy
  95. Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia
    James C. Ballenger · 2007 · Yearbook of Psychiatry and Applied Mental Health
  96. Clozapine-resistant Schizophrenia: Strategies for the Busy Clinician
    Mansi Jain · 2017 · Indian Journal of Private Psychiatry
  97. Response to Thornton et al.
    Tarek K. Rajji · 2015 · American Journal of Psychiatry
  98. Antipsychotic Drugs
    DONALD C. GOFF, Oliver Freudenreich, David C. Henderson · 2008 · Elsevier eBooks
  99. Smoking, plasma concentration, antipsychotic polypharmacy and adverse drug reaction burden in clozapine outpatients
    Timothy David Tanzer, Emilie Rutland, Nicola Warren, Michael A. Barras, Steve R Kisely, Dan J. Siskind · 2026 · Australian & New Zealand Journal of Psychiatry
  100. Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?
    Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Masaru Mimura · 2012 · Springer eBooks